AstraZeneca's chief executive has made public statements regarding the pharmaceutical company's strategic approach to drug development and market distribution. The CEO indicated that the company could potentially withhold new medications from European markets, though specific details about the circumstances or timeline were not elaborated.

Separately, the executive highlighted the growing role of artificial intelligence in the company's drug development processes. According to the CEO, AI technologies are fundamentally changing how pharmaceutical research is conducted and are contributing to improved success rates in bringing new treatments to market.

The statements come amid ongoing discussions within the pharmaceutical industry about regulatory environments, market access, and the integration of new technologies into traditional drug discovery methods. AstraZeneca, like other major pharmaceutical companies, has been investing in AI-powered research tools to streamline the lengthy and expensive process of developing new medications.

The pharmaceutical industry has increasingly turned to artificial intelligence to help identify promising drug compounds, predict potential side effects, and optimize clinical trial designs. These technological advances are seen as potentially reducing the time and cost associated with bringing new treatments from laboratory to patient.